Hong Kong CEO & Director Dealings (30 Mar): Tian An, CSPC Pharmaceutical, Li Auto
The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...
322 Views
CanSino Biologics (6185.HK) 2022 Results - It Is Time to Reassess CanSino and Its Future Prospects
CanSino had poor performance last year,but share price could bounce back in the next “sector resonance".There's no long-term investment value until...
295 Views
China Clears First Homegrown MRNA Covid Vaccine
China approved its first homegrown Covid-19 vaccine using the advanced mRNA technology, months after the country pivoted from its “zero-Covid”...
407 Views
CSPC Pharmaceutical (1093 HK): Double-Digit Sales and Profit Growth in 2022; MRNA Vaccine Approval
During 2022, CSPC reported 11% and 13% revenue and net profit growth, respectively. The company’s self-developed mRNA COVID-19 vaccine has won...
295 Views
Hanall Biopharma (009420 KS): Lead Pipeline Asset Moved a Step Closer to Commercialization in China
Hanall’s partner has reported positive top-line results from Phase 3 trial of batoclimab in myasthenia gravis in China. The partner plans to file...
401 Views